The estimated Net Worth of Jaisim Shah is at least $11.4 Миллион dollars as of 15 June 2017. Mr. Shah owns over 10,002 units of Sorrento Therapeutics Inc stock worth over $1,126 and over the last 22 years he sold SRNE stock worth over $450,202. In addition, he makes $10,971,100 as Director at Sorrento Therapeutics Inc.
Jaisim has made over 16 trades of the Sorrento Therapeutics Inc stock since 2003, according to the Form 4 filled with the SEC. Most recently he bought 10,002 units of SRNE stock worth $17,904 on 15 June 2017.
The largest trade he's ever made was buying 27,189 units of Sorrento Therapeutics Inc stock on 3 August 2015 worth over $312,674. On average, Jaisim trades about 4,661 units every 163 days since 2003. As of 15 June 2017 he still owns at least 112,633 units of Sorrento Therapeutics Inc stock.
You can see the complete history of Mr. Shah stock trades at the bottom of the page.
Jaisim Shah serves as Director of the Company. He has more than 25 years of global biopharma experience including over 15 years in senior management leading business development, commercial operations, investor relations, marketing and medical affairs. Mr. Shah has served as the President and Chief Executive Officer and board member of Scilex Holding Company since its inception in March 2019. He has also served as the Chief Executive Officer and a board member of Semnur Pharmaceuticals, Inc. since its inception in 2013. Prior to Semnur, Mr. Shah was a consultant to several businesses, including Sorrento Therapeutics, Inc., and was the Chief Business Officer of Elevation Pharmaceuticals, where Mr. Shah led a successful sale of Elevation to Sunovion in September 2012. Prior to Elevation, Mr. Shah was president of Zelos Therapeutics, where Mr. Shah focused on financing and business development. Prior to Zelos, Mr. Shah was the Senior Vice President and Chief Business Officer at CytRx, a biopharmaceutical company. Previously, Mr. Shah was Chief Business Officer at Facet Biotech and PDL BioPharma where he completed numerous licensing/partnering and strategic transactions with pharmaceutical and biotech companies. Prior to PDL, Mr. Shah was at Bristol-Myers Squibb, most recently as Vice President of Global Marketing where he received the “President’s Award” for completing one of the most significant collaborations in the company’s history. Previously, Mr. Shah was at F. Hoffman-La Roche in international marketing and was global business leader for corporate alliances with Genentech and Idec.
As the Director of Sorrento Therapeutics Inc, the total compensation of Jaisim Shah at Sorrento Therapeutics Inc is $10,971,100. There are no executives at Sorrento Therapeutics Inc getting paid more.
Jaisim Shah is 59, he's been the Director of Sorrento Therapeutics Inc since 2019. There are 3 older and 9 younger executives at Sorrento Therapeutics Inc. The oldest executive at Sorrento Therapeutics Inc is Dr. Michael A. Royal, 67, who is the SVP & Chief Medical Officer.
Jaisim's mailing address filed with the SEC is C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTORS PLACE, SAN DIEGO, CA, 92121.
Over the last 15 years, insiders at Sorrento Therapeutics Inc have traded over $17,198,839 worth of Sorrento Therapeutics Inc stock and bought 10,353,437 units worth $10,703,222 . The most active insiders traders include Jane Ph D Hsiao, Edgar Lee и Patrick Chan Soon Shiong Fa.... On average, Sorrento Therapeutics Inc executives and independent directors trade stock every 60 days with the average trade being worth of $2,947. The most recent stock trade was executed by Henry Ji on 7 September 2022, trading 88,888 units of SRNE stock currently worth $179,554.
sorrento therapeutics is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases. sorrento's lead products are multiple late-stage biosimilar and biobetter antibodies, as well as clinical car-t therapies targeting solid tumors.
Sorrento Therapeutics Inc executives and other stock owners filed with the SEC include: